Navigation Links
InterMune to Present at Bank of America Merrill Lynch Health Care Conference
Date:5/4/2011

BRISBANE, Calif., May 4, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Bank of America Merrill Lynch 2011 Health Care Conference in Las Vegas, NV on May 11, 2011, at 1:00 p.m. PDT.  

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com.  The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes Esbriet® (pirfenidone), which is now approved in the European Union for the treatment of adults with mild to moderate IPF, a progressive and fatal lung disease.  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
2. InterMune to Release First Quarter Financial Results on April 28
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
4. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbrietâ„¢ (Pirfenidone) in Europe
5. InterMune to Release Third Quarter Financial Results on October 28
6. InterMune Sells Danoprevir Rights to Roche for $175 Million
7. InterMune to Present at 2010 Citi Health Care Conference
8. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
9. InterMune to Release First Quarter Financial Results on April 29
10. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
11. InterMune Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
Breaking Biology News(10 mins):